Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
On Nov. 2, 2020, Walgreens Boots Alliance (WBA) and McKesson announced the completion of their previously announced agreement…
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
On Oct. 6, 2020, Pfizer and BioNTech announced initiation of a rolling submission to the European Medicines Agency…
On Sept. 30, 2020, researchers at the Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary…
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
On Sept. 29, 2020, In a new Letter, published in PNAS, researchers at La Jolla Institute for Immunology…
On Sept. 24, 2020, an international research team led by the Max Planck Institute for Evolutionary Anthropology in…
On Sept. 17, 2020, BioNTech announced an agreement with Novartis to acquire their GMP certified manufacturing facility in…
On Sept. 15, 2020, BioNTech announced that had receive a grant of up to 375 million Euro from…
On Sept. 12, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
On Sept. 7, 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, had approved the…
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
On Aug. 20, 2020, OpGen announced that its subsidiary Curetis GmbH had obtained the CE mark certification in…
On Aug. 20, 2020, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their U.S….
On Aug. 14, 2020, AstraZeneca concluded an agreement with the European Commission (EC) to supply up to 400…
On Aug. 12, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their BNT162 mRNA-based vaccine development…
On Aug. 5, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced that the first 72 participants had been dosed…
On Aug. 5, 2020, Pfizer Canada and BioNTech announced an agreement with the Government of Canada to supply…